Clinical Trial

Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)

Study acronym: EMPA-PKD
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The EMPA-PKD trial is assessing the safety of empagliflozin in patients with rapid progressive ADPKD with and without concomitant tolvaptan use by monitoring kidney growth and the rate of loss of kidney function.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-29; most recent amendment 2025-11-19.
Status change: Recruiting → Active, Not Recruiting 2025-11-19
Status change: Not Yet Recruiting → Recruiting 2024-06-17
Trial Details
NCT Number NCT06391450
Lead Sponsor Hannover Medical School
Collaborators: Boehringer Ingelheim
Conditions Autosomal Dominant Polycystic Kidney
Enrollment 44 participants
Start Date 2024-06-14
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-11-24